Company Filing History:
Years Active: 2022-2023
Title: Shunsuke Takenaka: Innovator in Therapeutic Antibodies
Introduction
Shunsuke Takenaka is a distinguished inventor based in Thousand Oaks, CA, known for his impactful contributions in the field of biotechnology. With two patents to his name, his work primarily focuses on novel therapeutics that utilize interleukin-21 muteins and anti-PD-1 antibody conjugates.
Latest Patents
Shunsuke's latest innovations include two significant patents. The first patent describes "Interleukin-21 mutein/ anti-PD-1 antibody conjugates", which provides IL-21 muteins and fusion proteins for treating various diseases. This disclosure includes related conjugates, nucleic acids, vectors, host cells, pharmaceutical compositions, and kits, as well as methods for making these IL-21 muteins and fusion proteins. The second patent centers around "Anti-PD-1 antibodies and methods of treatment", wherein it outlines PD-1 antigen-binding proteins, along with related nucleic acids, vectors, host cells, and pharmaceutical compositions for therapeutic applications. Methods for producing these PD-1 binding proteins and treating subjects in need are also presented.
Career Highlights
Shunsuke Takenaka currently works at Amgen Inc., a renowned biotechnology company that focuses on the discovery, development, and delivery of innovative human therapeutics. His role in the company highlights the integration of cutting-edge research with practical applications in disease treatment, showcasing his commitment to advancing healthcare solutions.
Collaborations
In his professional journey, Shunsuke has collaborated with notable colleagues, including Khaled M K Z Ali and Neeraj Jagdish Agrawal. These partnerships reflect a collaborative spirit that drives innovation, leading to valuable developments in biopharmaceuticals.
Conclusion
Shunsuke Takenaka continues to push the boundaries of therapeutic innovation through his patents and work at Amgen Inc. His contributions hold considerable promise for the advancement of medical treatments, particularly in the realm of immunotherapy. With a focus on interleukin and PD-1 targeting therapies, his inventions are set to make a significant impact on patients' lives.